We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesValneva SE ADR

Valneva SE ADR

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
5.87 USD -0.05 ( 0.84%)
Last update at 2026-11-12T14:53:00Z
VOLUME
1302
Market Cap
592.79M

Momentum Score

…

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.87
Low
5.87
High
52 Week Price Range
6.58
Low
17.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.92
Dividend Yield
-
Revenue TTM
152.96M
Revenue Per Share
2.20
Gross Profit TTM
-68.06M
Debt / Equity
1.63
ROE
-12.38%
Net Debt
82.74M
ROCE
-36.53%
Diluted EPS TTM
-0.41

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -144.81M -69.98M -65.30M -0.87M 3.35M
Net income -143.28M -73.42M -64.39M -1.74M 3.26M
Selling general administrative 34.07M 47.61M 38.01M 27.51M 36.30M
Selling and marketing expenses 23.51M 23.64M 7.51M 14.62M 11.74M
Gross profit 36.86M 160.16M 56.02M 76.23M 69.60M
Reconciled depreciation 21.04M 14.28M 9.80M 8.61M 6.83M
Ebit -113.44M -61.39M -55.11M 1.50M 7.57M
Ebitda -113.17M -46.87M -45.32M 10.11M 14.40M
Depreciation and amortization 0.27M 14.53M 9.79M 8.61M 6.83M
Operating income -113.44M -61.39M -55.11M 1.50M 6.26M
Other operating expenses 474.75M 409.48M 165.43M 126.92M 106.77M
Interest expense 19.05M 16.96M 10.74M 2.63M 3.79M
Tax provision -1.54M 3.45M -0.91M 0.87M 0.09M
Interest income 0.26M 0.25M 0.12M 0.20M 0.18M
Net interest income -18.79M -16.71M -10.62M -2.43M -3.61M
Income tax expense 1.54M 3.45M 0.91M 0.87M 0.09M
Total revenue 361.30M 348.08M 110.32M 126.20M 113.03M
Total operating expenses 150.31M 221.56M 111.13M 76.95M 63.34M
Cost of revenue 324.44M 187.92M 54.30M 49.97M 43.43M
Total other income expense net -31.37M -8.59M -10.19M -2.37M 0.69M
Net income from continuing ops -143.28M -73.42M -64.39M -1.74M 3.26M
Net income applicable to common shares - -73.42M -64.39M -1.74M 3.26M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 469.39M 621.34M 817.35M 449.16M 264.72M
Intangible assets 25.57M 28.71M 32.70M 35.41M 41.81M
Other current assets 50.63M 74.08M 71.04M 57.83M 14.92M
Total liab 341.14M 401.55M 646.77M 371.74M 129.57M
Total stockholder equity 128.25M 219.80M 170.58M 77.42M 135.15M
Deferred long term liab - 1.39M 1.58M 1.74M 1.95M
Other current liab 88.64M 189.50M 218.69M 51.71M 26.98M
Common stock 20.84M 20.75M 15.79M 13.65M 13.64M
Capital stock 20.84M 20.75M 15.79M 13.65M 13.64M
Retained earnings -551.68M -450.25M -306.97M -233.55M -176.22M
Other liab - - 173.38M 100.11M 7.36M
Other assets - -0.00M -0.00M 26.78M 24.10M
Cash 126.08M 289.43M 346.64M 204.39M 64.44M
Total current liabilities 158.86M 277.39M 368.98M 175.87M 41.30M
Current deferred revenue 5.70M 9.41M 124.02M 89.58M 1.14M
Net debt 82.74M -137.05M -231.99M -98.94M 20.78M
Short term debt 46.96M 36.99M 10.24M 9.68M 4.31M
Short long term debt 44.08M 11.58M 7.11M 6.99M 2.00M
Short long term debt total 208.82M 152.38M 114.66M 105.45M 85.22M
Other stockholder equity 593.36M 594.04M 409.26M 244.98M 297.73M
Property plant equipment - - 173.83M 78.15M 69.34M
Total current assets 262.82M 424.66M 585.83M 308.43M 129.16M
Long term investments - 0.00M 2.12M 2.13M 2.26M
Net tangible assets - 192.48M 139.46M 43.75M 95.29M
Net receivables 41.65M 23.91M 44.01M 19.23M 24.03M
Long term debt 132.77M 87.23M 50.73M 46.38M 24.32M
Inventory 44.47M 35.10M 124.10M 26.93M 25.77M
Accounts payable 17.56M 41.49M 16.04M 24.90M 8.87M
Accumulated other comprehensive income 65.73M 55.25M 52.51M 52.34M -31.16M
Common stock total equity - - - 13.65M 13.64M
Non currrent assets other 8.49M 8.30M 19.28M 19.47M 17.16M
Non current assets total 206.57M 196.69M 231.52M 140.74M 135.56M
Capital lease obligations 31.97M 53.57M 56.82M 52.09M 58.90M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -29.05M -93.12M -19.34M -10.69M -2.92M
Change to liabilities -133.90M 74.35M 94.67M 10.24M 2.41M
Total cashflows from investing activities - -93.12M -19.34M -10.69M -2.92M
Net borrowings - -3.90M 26.16M -2.61M -14.15M
Total cash from financing activities 215.12M 154.50M 21.74M -7.70M 30.95M
Change to operating activities -108.71M 134.85M 99.76M 6.37M -0.00M
Net income -143.28M -73.42M -64.39M -1.74M 3.26M
Change in cash -57.21M 142.29M 140.00M -12.64M 43.54M
Begin period cash flow 346.64M 204.39M 64.44M 77.08M 33.55M
End period cash flow 289.43M 346.69M 204.44M 64.44M 77.08M
Total cash from operating activities -245.34M 76.90M 137.74M 5.53M 16.31M
Issuance of capital stock 189.84M 166.82M 0.29M 0.02M 49.29M
Depreciation 21.04M 14.28M 9.80M 8.61M 6.83M
Other cashflows from investing activities - 0.06M 0.11M 0.20M 0.18M
Dividends paid 0.00M 0.00M 0.00M 0.00M 0.00M
Change to inventory 84.22M -92.37M -4.20M -2.42M -2.79M
Change to account receivables 12.40M -21.35M -24.02M -17.28M 4.34M
Sale purchase of stock - - - -2.48M -0.02M
Other cashflows from financing activities 30.12M -7.56M 45.56M 6.45M -2.75M
Change to netincome 22.88M 40.56M 26.12M 1.83M 2.26M
Capital expenditures 29.32M 93.17M 19.47M 10.88M 3.17M
Change in working capital -145.98M 36.13M 166.21M -3.00M 2.99M
Stock based compensation -8.66M 14.51M 6.33M 2.55M 1.89M
Other non cash items 33.07M 81.96M 20.70M -1.76M 1.25M
Free cash flow -274.67M -16.27M 118.27M -5.36M 13.13M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VALN
Valneva SE ADR		 -0.05
0.84%		 5.87 - 10000.00 3.85 4.30 4.48 -11.92
NVO
Novo Nordisk A/S		 -0.54
1.32%		 40.55 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.37
0.43%		 544.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -2.77
0.29%		 956.64 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Valneva SE ADR

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

6 rue Alain Bombard, Saint-Herblain, France, 44800

33 2 28 07 37 10

https://valneva.com

676

Name Title Year Born
Mr. Thomas Lingelbach Chairman of the Management Board, Pres & CEO 1963
Mr. Franck Grimaud MBA Director Gen., Chief Bus. Officer & Member of Management Board 1967
Mr. Frederic Jacotot VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board 1965
Dr. Juan-Carlos Jaramillo M.D. Chief Medical Officer & Member of the Management Board 1971
Mr. Peter Buhler CFO & Management Board Member 1971
Mr. Perry Celentano Interim Chief Operating Officer NA
Ms. Dipal Patel Chief Commercial Officer & Member of Management Board NA
Mr. Joshua Drumm Ph.D. VP of Investor Relations NA
Ms. Laetitia Bachelot-Fontaine VP of Global Communications & European Investor Relations NA
Mr. Gerald Strohmaier VP of Human Resource NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…